Silencing of S100A11 in intrahepatic cholangiocarcinoma can reduce the level of SMAD2/3 phosphorylation which is induced by TGF-β1, and then inhibit cell migration, invasion and epithelial-mesenchymal transition (EMT) [27]. Here, S100A11 is linked to intrahepatic cholangiocarcinoma.